Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables for 6 consecutive years, with $40.0 million as the latest value for Q2 2025.

  • Quarterly Receivables rose 2247.42% to $40.0 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $40.0 million through Jun 2025, up 2247.42% year-over-year, with the annual reading at $900000.0 for FY2024, 95.21% down from the prior year.
  • Receivables for Q2 2025 was $40.0 million at Kymera Therapeutics, up from $900000.0 in the prior quarter.
  • The five-year high for Receivables was $40.0 million in Q2 2025, with the low at $900000.0 in Q4 2024.
  • Average Receivables over 5 years is $8.6 million, with a median of $1.9 million recorded in 2021.
  • The sharpest move saw Receivables crashed 95.21% in 2024, then surged 2247.42% in 2025.
  • Over 5 years, Receivables stood at $1.8 million in 2021, then skyrocketed by 42.37% to $2.5 million in 2022, then surged by 652.0% to $18.8 million in 2023, then plummeted by 95.21% to $900000.0 in 2024, then soared by 4344.44% to $40.0 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $40.0 million, $900000.0, and $1.3 million for Q2 2025, Q4 2024, and Q3 2024 respectively.